Bionamic

Bionamic

Stockholm, Sweden· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Bionamic is a private, early-revenue stage software company offering a specialized platform for the antibody therapeutics sector. Its core product is a flexible, browser-based application that acts as a single source of truth for all antibody data, addressing significant inefficiencies in biopharma R&D data management. The company targets research labs and biopharma companies, aiming to accelerate antibody discovery and development by digitizing and connecting disparate data points across the entire workflow, from binder selection to CMC.

Digital HealthAI / Machine LearningDiagnostics

Technology Platform

A cloud-based, browser-first software platform that serves as an integrated data management, analysis, and workflow system for antibody discovery and development. It combines a flexible UI for life scientists with scripting for bioinformaticians to track biological entities, analyze assays, visualize data, and automate processes from early research through CMC.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The rapid growth and increasing complexity of the antibody therapeutics market creates a strong demand for specialized digital tools.
The slow digitalization of biopharma labs presents a large, underserved market for a platform that can integrate disparate data and streamline the entire development workflow from discovery to CMC.

Risk Factors

Competition from larger, established life science software vendors and the challenge of displacing entrenched, manual workflows in research labs.
As a private, early-revenue company, it faces execution and funding risks to achieve scale and continuous product development.

Competitive Landscape

Bionamic competes in the life science R&D software market against broad-platform ELN/LIMS providers like Benchling and Dotmatics, as well as niche tools for specific assay analysis. Its key differentiation is a deep, specialized focus on the antibody workflow, a flexible data model based on biological relations, and a platform that supports both intuitive use by scientists and advanced automation.